中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
INHIBITORY EFFECTS OF HOMOHARRINGTONINE AND HYDROXYCAMPTOTHECIN IN COMBINATION WITH OTHER AGENTS ON CANCER CELL-GROWTH

文献类型:期刊论文

作者ZHANG, SD; SHEN, LY; XU, B
刊名ASIA PACIFIC JOURNAL OF PHARMACOLOGY
出版日期1992-09
卷号7期号:3页码:191-195
关键词HOMOHARRINGTONINE HYDROXYCARNPTOTHECIN DRUG COMBINATION CYTOTOXIC EFFECT
ISSN号0217-9687
文献子类Article
英文摘要The inhibitory effects of homoharringtonine (HHT) and hydroxycamptothecin (HCPT), used singly or in combination with methotrexate (MTX), adriamycin (ADM), or verapamil (VER), were investigated using a colorimetric assay and a photometric reading method in murine leukemia P388 and hepatoma (HepA) cells. The data analyzed with the computer software of median effect principle suggested that both regimens (HHT + MTX and HCPT + ADM) at a drug exposure time of 4 h could synergically inhibit the growth of tumor cells. The synergism was more obvious as the drug exposure time was extended to 24 h. Moreover, it was noticed that the cytotoxic effect of HHT on P388 cells was significantly augmented by VER at an appropriate drug exposure period.
WOS研究方向Pharmacology & Pharmacy
语种英语
WOS记录号WOS:A1992JW73300006
出版者SINGAPORE UNIV PRESS
源URL[http://119.78.100.183/handle/2S10ELR8/275150]  
专题院士及顾问专家
药物安全性评价中心
作者单位CHINESE ACAD SCI,SHANGHAI INST MAT MED,SHANGHAI 200031,PEOPLES R CHINA
推荐引用方式
GB/T 7714
ZHANG, SD,SHEN, LY,XU, B. INHIBITORY EFFECTS OF HOMOHARRINGTONINE AND HYDROXYCAMPTOTHECIN IN COMBINATION WITH OTHER AGENTS ON CANCER CELL-GROWTH[J]. ASIA PACIFIC JOURNAL OF PHARMACOLOGY,1992,7(3):191-195.
APA ZHANG, SD,SHEN, LY,&XU, B.(1992).INHIBITORY EFFECTS OF HOMOHARRINGTONINE AND HYDROXYCAMPTOTHECIN IN COMBINATION WITH OTHER AGENTS ON CANCER CELL-GROWTH.ASIA PACIFIC JOURNAL OF PHARMACOLOGY,7(3),191-195.
MLA ZHANG, SD,et al."INHIBITORY EFFECTS OF HOMOHARRINGTONINE AND HYDROXYCAMPTOTHECIN IN COMBINATION WITH OTHER AGENTS ON CANCER CELL-GROWTH".ASIA PACIFIC JOURNAL OF PHARMACOLOGY 7.3(1992):191-195.

入库方式: OAI收割

来源:上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。